Cabaletta Bio (CABA) Net Income towards Common Stockholders (2018 - 2025)

Cabaletta Bio has reported Net Income towards Common Stockholders for 8 years, with the latest figure at -$41.8 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 28.4% year-over-year to -$41.8 million; the trailing twelve-month figure through Dec 2025 stood at -$168.2 million (down 45.18% YoY), and the FY2025 full-year result was -$168.2 million, down 45.18% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$41.8 million, up from -$45.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$9.7 million in Q1 2021, with the low at -$45.4 million in Q3 2025.
• Average Net Income towards Common Stockholders over 5 years is -$22.6 million, with a median of -$16.2 million recorded in 2023.
• Year-over-year, Net Income towards Common Stockholders increased 1.15% in 2022 and tumbled 90.53% in 2024.
• Tracing CABA's Net Income towards Common Stockholders over 5 years: stood at -$13.9 million in 2021, then retreated by 12.99% to -$15.7 million in 2022, then slumped by 33.1% to -$20.9 million in 2023, then slumped by 56.02% to -$32.6 million in 2024, then retreated by 28.4% to -$41.8 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$41.8 million (Q4 2025), -$45.4 million (Q3 2025), and -$45.1 million (Q2 2025), per Business Quant data.

Peer Comparison